B. Riley analyst Dave Kang raised the firm’s price target on Viavi (VIAV) to $12 from $10 and keeps a Neutral rating on the shares. The company’s ...

B. Riley raised the firm’s price target on Verastem (VSTM) to $9 from $7 and keeps a Buy rating on the shares after speaking with management. The ...

Learn about the latest financial trends and strategies in our comprehensive article written by a financial expert.

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.97% of ...

B. Riley issued their Q1 2025 earnings estimates for Customers Bancorp in a research note issued to investors on Monday, ...

b. riley financial, inc. is a publicly traded, diversified financial services company which takes a collaborative approach to the capital raising and financial advisory needs of public and private ...

B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $20 from $15 and keeps a Buy rating ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...

B. Riley analyst Mike Crawford upgraded Redwire (RDW) to Buy from Neutral with a price target of $27, up from $9.50. The firm increased fiscal ...

The deferral affects B. Riley’s 6.875% Series A and 7.375% Series B preferred stock, according to a statement Monday. Dividends on those preferreds cost the company $2 million in the second ...

B. Riley Financial Inc. suspended dividends on a pair of its preferred shares, holding off on cash payments to some investors ...